Iovance Biotherapeutics, Inc. (IOVA)

Last Closing Price: 12.38 (2022-08-10)

Company Description

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-342.25M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 3.99
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -64.21%
Return on Assets (Trailing 12 Months) -51.59%
Current Ratio (Most Recent Fiscal Quarter) 6.72
Quick Ratio (Most Recent Fiscal Quarter) 6.72
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $3.01
Earnings per Share (Most Recent Fiscal Quarter) $-0.63
Earnings per Share (Most Recent Fiscal Year) $-2.23
Diluted Earnings per Share (Trailing 12 Months) $-2.39
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 157.17M
Free Float 145.22M
Market Capitalization $1.89B
Average Volume (Last 20 Days) 2.57M
Beta (Past 60 Months) 0.47
Percentage Held By Insiders (Latest Annual Proxy Report) 7.60%
Percentage Held By Institutions (Latest 13F Reports) 99.07%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%